OncoMatch/Clinical Trials/NCT06219980
SBRT Followed by Neoadjuvant Chemoimmunotherapy of Sindilizumab Plus Docetaxel and Cisplatin for Locoregionally Advanced Squamous Carcinoma of Oral Cavity and Oropharynx
Is NCT06219980 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies SBRT+chemoimmunotherapy for sbrt.
Treatment: SBRT+chemoimmunotherapy — In resectable locally advanced oral cavity cancer and oropharyngeal cancer, SBRT with the total dose of 18 Gy by three fractions will be delivered to the primary tumor and metastatic lymph nodes every other day. One week later, neoadjuvant chemoimmunotherapy of Sindilizumab (200mg) plus docetaxel (75mg/m2) and cisplatin (75mg/m2) will be administered every three weeks for three cycles. Then radical surgical resection will be performed and postoperative radiotherapy with or without chemotherapy will be supplemented according to the initial tumor staging and postoperative pathologic characteristics. The investigators aim to evaluate the pathological complete response rate and safety of the combined treatment of SBRT with chemoimmunotherapy in locally advanced cancers of oral cavity and oropharynx.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage III, IVA
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1 therapy
Prior use of anti-PD-1 antibody
Cannot have received: anti-PD-L1 therapy
Prior use of anti-PD-L1 antibody
Cannot have received: anti-PD-L2 therapy
Prior use of anti-PD-L2 antibody
Cannot have received: anti-CTLA-4 therapy
Prior use of anti-CTLA-4 antibody
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify